Elusys Therapeutics, Inc. Awarded Additional $14.5 Million Under Existing U.S. Government Contracts Supporting Expanded Human Safety Studies of ETI-204 for Treatment of Inhalational Anthrax
9/17/2012 10:01:20 AM
More...
|
Elusys Therapeutics, Inc. Receives Additional $14.5 Million Funding From U.S. Govt. to Support Expanded Human Safety Studies of ETI-204
9/17/2012 7:12:49 AM
More...
|
Elusys Therapeutics, Inc. Gets $50.2 Million to Advance Investigational Anthrax Treatment
8/3/2012 8:05:55 AM
More...
|
Elusys Therapeutics, Inc. Initiates Third Clinical Safety Study of Anthim, a New Anthrax Treatment; Company Successfully Completes Manufacturing at Commercial Scale
10/24/2011 2:27:09 PM
More...
|
Elusys Therapeutics, Inc. Awarded $68 Million Contract to Develop Anthim for Intramuscular Pre- and Post-Exposure Prophylaxis of Anthrax Infection
9/8/2011 8:05:33 AM
More...
|
Elusys Therapeutics, Inc. Awarded Additional $40.6 Million Under Existing U.S. Government Contract to Fund Advanced Development of Anthim, a New Treatment for Anthrax
8/4/2010 11:24:45 AM
More...
|
Elusys Therapeutics, Inc. and Lonza Group Ltd. (LZAGY.PK) Extend Manufacturing Agreement for Anthim, a New Anthrax Treatment in Late-Stage Development
7/15/2010 7:44:30 AM
More...
|
Elusys Therapeutics, Inc. Receives Contract for up to $143 Million from the U.S. Federal Government to Fund Advanced Development of Anthim(R), a New Treatment for Anthrax
1/5/2010 7:13:07 AM
More...
|
Biomedical Advanced Research and Development Authority (BARDA) Awards Elusys Therapeutics, Inc. up to $143 Million for Advanced Development of a New Drug to Treat Anthrax
12/28/2009 7:28:53 AM
More...
|
Elusys Therapeutics, Inc. and Lonza Enter Into Manufacturing Agreement
6/16/2009 8:58:37 AM
More...
|
|